Evaluation and Treatment of Painful Peripheral Polyneuropathy

ABSTRACT

Pain is a common component of sensory peripheral polyneuropathy and occurs primarily as a consequence of injury to small, unmyelinated C-fiber nerve axons. This class of fibers is particularly vulnerable to metabolic injury, and the neuropathy manifests in a length-dependent pattern. Diabetes mellitus, prediabetes associated with insulin resistance, toxins, and drugs are common causes of painful neuropathy, but a substantial percentage are idiopathic. Pathogenesis of neuropathic pain involves loss of peripheral axons and inappropriate peripheral and central adaptation of neuronal signaling to this loss. Treatment of painful neuropathy should be directed at removing the offending metabolic injury, if possible. Antiepileptic drugs, tricyclic antidepressants, opiates, and other treatments have shown efficacy in clinical trials for symptomatic relief of neuropathic pain.

Allodynia - diabetes - evaluation - intraepidermal nerve fiber counting (IENF) - human immunodeficiency virus (HIV) - hyperalgesia - nerve conduction studies (NCS) - neuropathic pain - paresthesia - polyneuropathy - quantitative sudomotor axon reflex testing (QSART) - treatment

REFERENCES

• 1 Dyck P J, Oviatt K F, Lambert E H. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis.  Ann Neurol. 1981;  10 222-226
• 2 Low P A. Autonomic nervous system function.  J Clin Neurophysiol. 1993;  10 14-27
• 3 Novak V, Freimer M L, Kissel J T et al.. Autonomic impairment in painful neuropathy.  Neurology. 2001;  56 861-868
• 4 Dyck P J, Grant I A, Fealey R D. Ten steps in characterizing and diagnosing patients with peripheral neuropathy.  Neurology. 1996;  47 10-17
• 5 Periquet M I, Novak V, Collins M P et al.. Painful sensory neuropathy: prospective evaluation using skin biopsy.  Neurology. 1999;  53 1641-1647
• 6 Smith A G, Singleton J R. The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy.  Arch Intern Med. 2004;  164 1021-1025
• 7 Singleton J R, Smith A G, Bromberg M B. Painful sensory neuropathy associated with impaired glucose tolerance.  Muscle Nerve. 2001;  24 1225-1228
• 8 Singleton J R, Smith A G, Bromberg M B. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy.  Diabetes Care. 2001;  24 1448-1453
• 9 Periquet M I, Novak V, Collins M P et al.. Painful sensory neuropathy: prospective evaluation using skin biopsy.  Neurology. 1999;  53 1641-1647
• 10 Smith A G, Tripp C, Singleton J R. Skin biopsy findings in patients with neuropathy associated with diabetes and impaired glucose tolerance.  Neurology. 2001;  57 1701-1704
• 11 Holland N R, Stocks A, Hauer P, Cornblath D R, Griffin J W, McArthur J C. Intraepidermal nerve fiber density in patients with painful sensory neuropathy.  Neurology. 1997;  48 708-711
• 12 Herrmann D, Griffin J, Hauer P, Cornblath D R, McArthur J C. Epidermal nerve fiber density: association with sural nerve morphometry and electrophysiology in peripheral neuropathies.  Neurology. 1999;  52(suppl 2) A309-A310
• 13 Low P A, Vernino S, Suarez G. Autonomic dysfunction in peripheral nerve disease.  Muscle Nerve. 2003;  27 646-661
• 14 Holland N R, Crawford T O, Hauer P, Cornblath D R, Griffin J W, McArthur J C. Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases.  Ann Neurol. 1998;  44 47-59
• 15 Freeman R, Chase K P, Risk M R. Quantitative sensory testing cannot differentiate simulated sensory loss from sensory neuropathy.  Neurology. 2003;  60 465-470
• 16 Kang P B, Hoffman S N, Krimitsos E, Rutkove S B. Ambulatory foot temperature measurement: a new technique in polyneuropathy evaluation.  Muscle Nerve. 2003;  27 737-742
• 17 Woolf C J. Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy.  Life Sci. 2004;  74 2605-2610
• 18 Spruce M C, Potter J, Coppini D V. The pathogenesis and management of painful diabetic neuropathy: a review.  Diabet Med. 2003;  20 88-98
• 19 Woolf C J, Mannion R J. Neuropathic pain: aetiology, symptoms, mechanisms, and management.  Lancet. 1999;  353 1959-1964
• 20 Waxman S G, Cummins T R, Dib-Hajj S D, Black J A. Voltage-gated sodium channels and the molecular pathogenesis of pain: a review.  J Rehabil Res Dev. 2000;  37 517-528
• 21 Cummins T R, Dib-Hajj S D, Waxman S G. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy.  J Neurosci. 2004;  24 8232-8236
• 22 Woolf C J, Salter M W. Neuronal plasticity: increasing the gain in pain.  Science. 2000;  288 1765-1768
• 23 Noguchi K, Kawai Y, Fukuoka T, Senba E, Miki K. Substance P induced by peripheral nerve injury in primary afferent sensory neurons and its effect on dorsal column nucleus neurons.  J Neurosci. 1995;  15 7633-7643
• 24 Moore K A, Kohno T, Karchewski L A, Scholz J, Baba H, Woolf C J. Partial peripheral nerve injury promotes a selective loss of GABAergic inhibition in the superficial dorsal horn of the spinal cord.  J Neurosci. 2002;  22 6724-6731
• 25 Keay K A, Monassi C R, Levison D B, Bandler R. Peripheral nerve injury evokes disabilities and sensory dysfunction in a subpopulation of rats: a closer model to human chronic neuropathic pain?.  Neurosci Lett. 2004;  361 188-191
• 26 Dyck P J, Kratz J M, Karnes J L et al.. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.  Neurology. 1993;  43 817-824
• 27 Ziegler D, Gries F A, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy.  J Diabetes Complications. 1992;  6 49-57
• 28 Said G, Elgrably F, Lacroix C et al.. Painful proximal diabetic neuropathy: inflammatory nerve lesions and spontaneous favorable outcome.  Ann Neurol. 1997;  41 762-770
• 29 Pascoe M K, Low P A, Windebank A J, Litchy W J. Subacute diabetic proximal neuropathy.  Mayo Clin Proc. 1997;  72 1123-1132
• 30 Lehtinen J M, Uusitupa M, Siitonen O, Pyorala K. Prevalence of neuropathy in newly diagnosed NIDDM and nondiabetic control subjects.  Diabetes. 1989;  38 1307-1313
• 31 Cohen J A, Jeffers B W, Faldut D, Marcoux M, Schrier R W. Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin dependent diabetes mellitus (NIDDM).  Muscle Nerve. 1998;  21 72-80
• 32 Novella S P, Inzucchi S E, Goldstein J M. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy.  Muscle Nerve. 2001;  24 1229-1231
• 33 Sumner C J, Sheth S, Griffin J W, Cornblath D R, Polydefkis M. The spectrum of neuropathy in diabetes and impaired glucose tolerance.  Neurology. 2003;  60 108-111
• 34 Diabetes Control and Complications Trial Research Group . Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial.  Ann Neurol. 1995;  38 869-880
• 35 Diabetes Control and Complications Trial Research Group . The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial.  Diabetes. 1996;  45 1289-1298
• 36 Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
• 37 Tuomilehto J, Lindstrom J, Eriksson J G et al.. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
• 38 Perry R C, Baron A D. Impaired glucose tolerance: why is it not a disease?.  Diabetes Care. 1999;  22 883-885
• 39 Polydefkis M, Yiannoutsos C T, Cohen B A et al.. Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy.  Neurology. 2002;  58 115-119
• 40 Hahn K, Arendt G, Braun J S et al.. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies.  J Neurol. 2004;  251 1260-1266
• 41 Simpson D M, McArthur J C, Olney R et al.. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial.  Neurology. 2003;  60 1508-1514
• 42 Adams D. Hereditary and acquired amyloid neuropathies.  J Neurol. 2001;  248 647-657
• 43 Comenzo R L. Primary systemic amyloidosis.  Curr Treat Options Oncol. 2000;  1 83-89
• 44 van de Poel M H, Coebergh J W, Hillen H F. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands.  Br J Haematol. 1995;  91 121-125
• 45 Orstavik K, Mork C, Kvernebo K, Jorum E. Pain in primary erythromelalgia: a neuropathic component?.  Pain. 2004;  110 531-538
• 46 Schiffmann R, Floeter M K, Dambrosia J M et al.. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.  Muscle Nerve. 2003;  28 703-710
• 47 Hilz M J, Brys M, Marthol H, Stemper B, Dutsch M. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy.  Neurology. 2004;  62 1066-1072
• 48 Sinha S, Mahadevan A, Lokesh L et al.. Tangier disease-a diagnostic challenge in countries endemic for leprosy.  J Neurol Neurosurg Psychiatry. 2004;  75 301-304
• 49 Chin R L, Sander H W, Brannagan T H et al.. Celiac neuropathy.  Neurology. 2003;  60 1581-1585
• 50 Cicarelli G, Della Rocca G, Amboni M et al.. Clinical and neurological abnormalities in adult celiac disease.  Neurol Sci. 2003;  24 311-317
• 51 Windebank A J. Chemotherapeutic neuropathy.  Curr Opin Neurol. 1999;  12 565-571
• 52 Abernathy C O, Liu Y P, Longfellow D et al.. Arsenic: health effects, mechanisms of actions, and research issues.  Environ Health Perspect. 1999;  107 593-597
• 53 Moeschlin S. Thallium poisoning.  Clin Toxicol. 1980;  17 133-146
• 54 Schaumburg H H, Berger A. Alopecia and sensory polyneuropathy from thallium in a Chinese herbal medication.  JAMA. 1992;  268 3430-3431
• 55 Verstappen C C, Heimans J J, Hoekman K, Postma T J. Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.  Drugs. 2003;  63 1549-1563
• 56 Paulson O B, Melgaard B, Hansen H S et al.. Misonidazole neuropathy.  Acta Neurol Scand Suppl. 1984;  100 133-136
• 57 Blum A S, Dal Pan G J, Feinberg J et al.. Low-dose zalcitabine-related toxic neuropathy: frequency, natural history, and risk factors.  Neurology. 1996;  46 999-1003
• 58 Parry G J, Bredesen D E. Sensory neuropathy with low dose pyridoxine.  Neurology. 1985;  35 1466-1468
• 59 Schaumburg H, Kaplan J, Windebank A et al.. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome.  N Engl J Med. 1983;  309 445-448
• 60 Hallett M, Fox J G, Rogers A E et al.. Controlled studies on the effects of alcohol ingestion on peripheral nerves of macaque monkeys.  J Neurol Sci. 1987;  80 65-71
• 61 Bosch E P, Pelham R W, Rasool C G et al.. Animal models of alcoholic neuropathy: morphologic, electrophysiologic, and biochemical findings.  Muscle Nerve. 1979;  2 133-144
• 62 Monforte R, Estruch R, Valls-Sole J, Nicolas J, Villalta J, Urbano-Marquez A. Autonomic and peripheral neuropathies in patients with chronic alcoholism. A dose-related toxic effect of alcohol.  Arch Neurol. 1995;  52 45-51
• 63 Gorson K C, Ropper A H. Idiopathic small fiber neuropathy.  Acta Neurol Scand. 1995;  92 376-382
• 64 Sindrup S H, Jensen T S. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action.  Pain. 1999;  83 389-400
• 65 Namaka M, Gramlich C R, Ruhlen D, Melanson M, Sutton I, Major J. A treatment algorithm for neuropathic pain.  Clin Ther. 2004;  26 951-979
• 66 Max M B, Culnane M, Schafer S C et al.. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood.  Neurology. 1987;  37 589-596
• 67 Max M B, Lunch S A, Muir J, Shoaf S E, Smoller B, Dubner R. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy.  N Engl J Med. 1992;  326 1250-1256
• 68 Morello C M, Leckband S G, Stoner C P, Moorhouse D F, Sahagian G A. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain.  Arch Intern Med. 1999;  159 1931-1937
• 69 Polydefkis M, Allen R P, Hauer P, Earley C J, Griffin J W, McArthur J C. Subclinical sensory neuropathy in late-onset restless legs syndrome.  Neurology. 2000;  55 1115-1121
• 70 Backonja M M. Use of anticonvulsants for treatment of neuropathic pain.  Neurology. 2002;  59(suppl 2) S14-S17
• 71 Backonja M, Beydoun A, Edwards K R et al.. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.  JAMA. 1998;  280 1831-1836
• 72 Happe S, Klosch G, Saletu B, Zeitlhofer J. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin.  Neurology. 2001;  57 1717-1719
• 73 Fisher R S, Sachdeo R C, Pellock J, Penovich P E, Magnus L, Bernstein P. Rapid initiation of gabapentin: a randomized, controlled trial.  Neurology. 2001;  56 743-748
• 74 Gomez-Perez F J, Choza R, Rios J M et al.. Nortriptyline-fluphenazine vs. carbamazepine in the symptomatic treatment of diabetic neuropathy.  Arch Med Res. 1996;  27 525-529
• 75 Sindrup S H, Jensen T S. Pharmacotherapy for trigeminal neuralgia.  Clin J Pain. 2002;  18 22-27
• 76 Simpson D M, Olney R, McArthur J C, Khan A, Godbold J, Ebel-Frommer K. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy.  Neurology. 2000;  54 2115-2119
• 77 Watson C P. The treatment of neuropathic pain: antidepressants and opioids.  Clin J Pain. 2000;  16(suppl 2) S49-S55
• 78 Courteix C, Bardin M, Chantelauze C, Lavarenne J, Eschalier A. Study of the sensitivity of the diabetes-induced pain model in rats to a range of analgesics.  Pain. 1994;  57 153-160
• 79 Martin T J, Hairston C T, Lutz P O, Harris L S, Porreca F. Anti-allodynic actions of intravenous opioids in the nerve injured rat: potential utility of heroin and dihydroetorphine against neuropathic pain.  Eur J Pharmacol. 1998;  357 25-32
• 80 Harati Y, Gooch C, Swenson M et al.. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy.  J Diabetes Complications. 2000;  14 65-70
• 81 Harati Y, Gooch C, Swenson M et al.. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy.  Neurology. 1998;  50 1842-1846
• 82 Duhmke R M, Cornblath D D, Hollingshead J R. Tramadol for neuropathic pain.  Cochrane Database Syst Rev. 2004;  2 CD003726
• 83 Jarvis B, Coukell A J. Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.  Drugs. 1998;  56 691-707
• 84 Forst T, Pohlmann T, Kunt T et al. The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy.  Acta Diabetol. 2002;  39 1-6
• 85 Wolfe G I, Baker N S, Amato A A et al.. Chronic cryptogenic sensory polyneuropathy: clinical and abloratory characteristics.  Arch Neurol. 1999;  56 540-547
• 86 Wolfe G I, Barohn R J. Cryptogenic sensory and sensorimotor polyneuropathies.  Semin Neurol. 1998;  18 105-111
• 87 Notermans N C, Wokke J H, Franssen H et al.. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study in 75 patients.  J Neurol Neurosurg Psychiatry. 1993;  56 1066-1071
• 88 Verghese J, Bieri P L, Gellido C, Schaumburg H H, Herskovitz S. Peripheral neuropathy in young-old and old-old patients.  Muscle Nerve. 2001;  24 1476-1481